BMC Clinical Pharmacology

, 11:8 | Cite as

Comparison of renal effects of ibuprofen versus indomethacin during treatment of patent ductus arteriosus in contiguous historical cohorts

Open Access
Research article



Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as indomethacin in small randomized controlled trials, with possibly fewer adverse effects. However, adverse renal effects of ibuprofen have been noted in some trials and suspected in our practice.

The purpose of this study was to examine whether ibuprofen and indomethacin treatment of PDA have comparable effects on renal function as evidenced by urine output and serum creatinine.


Retrospective chart review of 350 patients. Serum creatinine and urine output were recorded prior to start of treatment, during each course and after the last course of treatment. Pre-treatment mean creatinine and urine output values were compared to treatment and post treatment means using 2-factor repeated measures ANOVA.


165 patients were treated with indomethacin (2005-2006) and 185 received ibuprofen (2007-2008). There was no difference between treatment groups in demographics or baseline renal function. For both groups, the number of treatment courses was inversely correlated with birth weight and gestational age. Analysis of the first course including all patients, revealed significant increase in creatinine and decrease in urine output with both drugs, with a more pronounced effect of indomethacin on creatinine. In the subgroup of 219 patients who received only one treatment course, there was a significant increase in creatinine after indomethacin, but not after ibuprofen. In the 131 who received 2 or more courses, the decrease in urine output and increase in creatinine were not different between drugs. There were significant decreases in urine output observed in the second and third courses of ibuprofen treatment (both by 0.9 mL/kg/hr).


Both drugs have a similar short-term effect on renal function. Indomethacin had a more prominent initial effect, while ibuprofen decreased renal function during the second and third courses similarly to indomethacin. The changes in renal function seen with ibuprofen treatment should be considered in fluid and electrolyte management, especially if treatment beyond one course is required.

List of abbreviations


patent ductus arteriosus


bronchopulmonary dysplasia


retinopathy of prematurity


necrotizing enterocolitis


intraventricular hemorrhage


periventricular leukomalacia


very low birth weight


Patent ductus arteriosus (PDA) is a common occurrence in very low birth weight (VLBW, ≤1500 g) infants, which often causes significant morbidities. Left-to-right shunting through the ductus may increase the risk of intraventricular hemorrhage [1, 2], necrotizing enterocolitis [3], bronchopulmonary dysplasia, and death [4, 5].

Successful pharmacological closure of PDA with indomethacin was first reported in 1976, with subsequent reports that indomethacin reduced neonatal morbidity [6, 7]. However, indomethacin may lead to complications such as transient or permanent renal dysfunction [8, 9], necrotizing enterocolitis, and reduced cerebral oxygenation [10]. These indomethacin-related complications have prompted researchers to seek safer pharmacological treatment for closure of PDA.

In recent years another cyclooxygenase inhibitor, ibuprofen, has been proposed for the treatment of PDA, and several randomized controlled trials have shown it to be as efficacious as indomethacin, with possibly fewer adverse effects [11]. It is thought that ibuprofen is better tolerated due to less effects on renal function, renal and mesenteric blood flow [12, 13, 14], and cerebral blood flow [15]. Adverse effects of ibuprofen have been noted in some trials [16] and suspected in our practice. This difference might be due to the fact that the infants in the previous trials were more mature (gestational age ~28 weeks) than the age of the infants at greatest risk for PDA (younger than 26 weeks); thus, it is difficult to extrapolate the clinical effects observed in those trials to the younger and unselected population typically treated in the clinical care context. Our primary objective was to ascertain whether ibuprofen and indomethacin treatment of PDA have comparable effects on renal function as evidenced by urine output and serum creatinine, during routine clinical usage.


Study design

This was a retrospective cohort study with a hypothesis that ibuprofen and indomethacin treatment of PDA have comparable effects on renal function as evidenced by urine output and serum creatinine. In October 2006 Neonatology staff switched from indomethacin to ibuprofen as the drug of choice for medical treatment of PDA. The cohort of neonates treated with indomethacin from January 2005 to October 2006 was compared to those treated with ibuprofen from October 2006 through December 2008. The study was approved by the Institutional Review Board of the Albany Medical Center, and exempted from requiring informed consent.

Patient population

Records were reviewed for inborn or outborn preterm neonates born at any gestation and birth weight, admitted to the NICU of Albany Medical Center Hospital (New York State-designated Level IV Regional Perinatal Center) and requiring treatment for PDA, from January 2005 through December 2008. The clinical approach to the PDA was unchanged throughout the study period and it is summarized here. Prophylactic indomethacin was not used in our institution. Cardiology consultation was requested if a symptomatic PDA was suspected (extremely low birth weight neonate, widened pulse pressures, murmur, bounding pulses, or significant respiratory disease) and an echocardiogram was performed. The size of the PDA was described qualitatively by the cardiologists (as absent, small, mild, moderate, large, or synonymous terms), along with blood flow direction. Attending neonatologists generally initiated medical treatment if predominant left-to-right shunting was noted through a PDA larger than "small", while also considering the patient's clinical status, expected course given postnatal age, and potential contraindications. The day after the last treatment dose was administered, a follow-up echo was performed, and another course of either ibuprofen or indomethacin was given based on the same criteria used for the initial course. The decision to use further courses of medical treatment or resort to surgical ligation was made jointly by the attending neonatologist, cardiologist and cardio-thoracic surgeon. A mildly restrictive fluid therapy regimen was used, beginning with a weight-based guideline, and then tailored to each infant's condition and postnatal age. The fluid regimen was further restricted (by approximately 20 mL/kg/day below the individualized daily target) as cyclooxygenase inhibitor therapy was initiated.

Indomethacin was dosed at 0.2 mg/kg/dose once, then 0.1 mg/kg/dose IV daily for 2 more doses for neonates <750 g; 0.2 mg/kg/dose daily for 3 doses for neonates 750 g to 1 kg; and 0.2 mg/kg/dose every 12 hours for those over 1 kg. Ibuprofen was dosed at 10 mg/kg/dose once and then 5 mg/kg/dose daily for 2 more doses.

Data collected

Demographic data were recorded into an Excel spreadsheet and de-identified. These data included gender, date of birth and date of discharge, birth weight, and gestational age. PDA-related data recorded included: date indomethacin or ibuprofen started, number of courses of medical treatment given, whether PDA was closed after the last treatment and whether surgical ligation of the PDA was performed.

Renal function prior to, during and after medical treatment of PDA was assessed by recording urine output and serum creatinine. Serum creatinine on the morning prior to administration of the first dose of ibuprofen or indomethacin was used as the baseline level. If no creatinine value was available from that day, the one from the prior day was used. During each treatment course, the last available serum creatinine was recorded. Resolution of the drug effect on renal function was assessed by evaluation of creatinine on the third to fifth day after the last drug dose.

Evaluation of urine output was done on the same schedule as creatinine, for 24 hours previous to, during treatment, and three to five days after the last dose of ibuprofen or indomethacin. Urine output was calculated as mL/kg/hour.

Secondary outcomes noted were necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), and retinopathy of prematurity (ROP). NEC (defined using Bell's criteria [17]), spontaneous intestinal perforation (defined using Vermont Oxford Network criteria [18]), NEC-like illness, and whether NEC required surgical intervention were recorded. NEC-like illness was defined by the presence of clinical symptoms and radiographic appearance of bowel ischemia without pneumatosis or portal gas on abdominal radiograph. BPD was defined as oxygen requirement at 36 weeks post-menstrual age. ROP exam and the stage of retinopathy were also evaluated [19]. Presence of IVH and periventricular leukomalacia (PVL) were recorded, as well as the stage of IVH [20].

Sample size and statistical analysis

An a-priori power analysis setting the α error at 0.05 and ß error at 0.20 revealed that a minimum of 50 patients in each group was required to detect a 20% difference in urine output - well within the expected size of the cohorts. SPSS for Windows (SPSS version 12.0.1, Chicago, IL), as well as Minitab (Minitab version 15.0, State College, PA) and Stata (Stata version 8, College Station, TX) were used to conduct statistical data analyses. Pre-treatment mean creatinine and urine output values were compared to treatment and post treatment means using 2-factor repeated measures ANOVA (generalized linear model, including terms for treatment, time, treatment-by-time interaction, and with patients nested within treatment group). Dunnett's post-hoc test was used to compare within-group changes in mean creatinine and urine output from baseline to each treatment course. A p value of < 0.05 was considered significant.

Chi-square analysis was performed to compare the proportion of patients experiencing the secondary outcomes of PDA closure, BPD, ROP, and NEC between treatment groups.

In order to assess whether there is a difference in the rate of PDA closure, number of doses of medical treatment required, or changes in renal function depending on gestational age or birth weight, these variables were evaluated in subgroup analyses. Gestational age categories were divided into: <25 weeks, 25 0/7-27 6/7 weeks, 28 0/7 - 29 6/7 weeks, and ≥ 30 0/7 weeks. Birth weight categories were divided into: ≤ 750 grams, 751 -1000 grams, 1001 - 1500 grams, and >1500 grams.


Of the 350 patients, 165 were treated with indomethacin and 185 received ibuprofen. The 7 cases where both drugs were used were excluded from the analyses of outcomes subsequent to the first course of treatment [Table 1].
Table 1

Baseline Population Characteristics




Birth Weight, grams (mean)



Birth Weight Categories, n (%)


≤ 750 grams

54 (33)

56 (30)

   751 - 1000 grams

38 (23)

41 (22)

   1001 - 1500 grams

51 (31)

54 (29)

> 1500 grams

22 (13)

35 (19)

Gestational Age, weeks (mean)



Gestational Age Categories, n (%)


< 25 weeks

33 (20)

34 (18)

   25 - 27 6/7 weeks

61 (37)

68 (37)

   28 - 29 6/7 weeks

35 (21)

37 (20)

≥ 30 weeks

36 (22)

47 (25)




82 (50)

108 (58) *


83 (50)

78 (42)

Number of courses, n (%)




101 (61)

118 (63)


41 (25)

28 (15)


19 (12)

37 (20)


4 (2)

2 (1)

Baseline urine output, mL/kg/h mean (SD)

3.9 (1.4)

4.2 (1.6)

Baseline creatinine, mg/dL mean (SD)

0.96 (0.2)

0.93 (0.2)

PDA, patent ductus arteriosus

* denotes statistically significant difference between treatments, p < 0.05

The overall efficacy was the same for ibuprofen (71%) and indomethacin (68%) [Table 2]. The rate of ligation overall was the same after treatment with indomethacin and ibuprofen, with the exception of the neonates that required 2 courses of treatment for PDA closure. More babies required PDA ligation after receiving 2 courses of indomethacin (53.7%) compared to ibuprofen (28.6%) (p < 0.05) [Table 3].
Table 2

Secondary Outcomes According to Treatment Group





(N = 161)

(N = 182)

p value

Day of Life at Start of Treatment (mean, SD)

3.3 ± 2.3

3.5 ± 2.7


PDA Closed, n (%)

109 (68)

129 (71)


PDA Ligation, n (%)

45 (28)

38 (21)


BPD, n (%)

72 (45)

90 (49)


NEC-related conditions, any, n (%)

27 (17)

32 (18)


NEC, n (%)

6 (4)

15 (8)


   NEC-Like Illness (%)

13 (8)

5 (3)


   Spontaneous Intestinal Perforations, n (%)

8 (5)

12 (7)


ROP, n (%)

65 (52)

41 (30)


Severe ROP: Grades III-V

15 (12)

15 (11)


IVH, any, n (%)

58 (36)

57 (31)


Severe IVH: Grade III/IV

12 (8)

12 (9)



4 (2.4)

3 (1.6)


Death, n (%)

12 (7)

16 (9)


PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia.

The denominator for the percent (%) for each secondary outcome reflects the number of patients with evaluation of that outcome - for ROP in particular, 82 infants did not have a retinal exam.

* denotes statistically significant difference between treatments, p < 0.05

Table 3

Treatment Efficacy by Number of Treatment Courses




Number of Courses Used







Total N







PDA Closed, n (%)

89 (88.1)

18 (43.9)

3 (15.8)

108 (92.3)

15 (53.6)

7 (18.9)

PDA Ligations

8 (7.9)

22 (53.7)*

15 (78.9)

3 (2.6)

8 (28.6)*

26 (70.3)

PDA, patent ductus arteriosus.

Not all patients whose PDA remained open needed to have a surgical ligation.

* denotes statistically significant difference between treatments, p < 0.05.

Date of birth was considered as day of life one. There was no difference in the initial treatment day between indomethacin and ibuprofen [Table 4]. Second and third treatment courses started at a median of one day after conclusion of the previous course. There was, also, no statistical difference in the intervals between first and second (p = 0.2) or second and third treatment courses (p = 0.4) [Table 4]. There was no difference between drug treatment groups in gestational age, birth weight, or baseline creatinine or urine output. We found a significantly larger proportion of male infants in the ibuprofen group (58% males; p = 0.04) [Table 1]. However, ANOVA with gender as a covariate revealed no significant gender effect on baseline urine output or creatinine values, nor in their response to each treatment; cross-tabulations revealed no statistically significant differences between genders in the number of treatment courses, PDA closure or ligation rates in the ibuprofen group (data not shown). The number of treatment courses had a significant (p = 0.0001) inverse relation with both birth weight and gestational age, in chi-square analyses.
Table 4

Treatment Start Day




Initial Day of Treatment














   Interquartile range



Days between 1st and 2nd courses














   Interquartile range



Days between 2nd and 3rd courses














   Interquartile range



When all patients were included in the analysis of the first treatment course, there was a statistically significant increase in creatinine (by 0.1 mg/dL) and decrease in urine output (by 0.3 mL/kg/hr) from baseline, after indomethacin [Figure 1][Table 5]. With ibuprofen treatment, only the increase in creatinine was significant. The ANOVA revealed that the increase in creatinine was significantly greater with indomethacin than with ibuprofen (p < 0.05 for both the treatment effect and the treatment-time interaction) [Table 5 and Figure 1]. However, there was no statistically significant difference in the effect of both drugs on urine output.
Figure 1

Mean urine output and creatinine values for all patients by drug. Comparison of mean urine output and creatinine values for all patients during the first course of therapy, by treatment drug. Indomethacin group (solid line) and Ibuprofen group (dashed line). PRE - pre-treatment baseline; 1st - end of first course of treatment. * denotes statistically significant (p < 0.05) change from treatment baseline; § denotes statistically significant (p < 0.05) difference in change from baseline between treatment groups.

Table 5

Effect of Each Initial Treatment Course on Renal Function




Comparison between treatments on changes from baseline (ANOVA)



1st course

p value for change with indomethacin (t-test)


1st course

p value for change with ibuprofen (t-test)

p value for main treatment effect

p value for treatment - time interaction

Urine output (mL/kg/hr; mean ± SD)

3.9 ± 1.4

3.6 ± 1.4

0.033 *

4.2 ± 1.6

4.0 ± 1.4




Serum Creatinine (mg/dL; mean + SD)

0.96 ± 0.21

1.06 ± 0.24


0.93 ± 0.2

0.98 ± 0.24

0.005 *


0.047 *

Supplemental analyses of the effect of each initial treatment course on renal function.

* denotes statistically significant (p < 0.05) change from baseline within a treatment group

In the subgroup of 219 patients who received only one course of therapy, there was a significant increase in creatinine (by 0.1 mg/dL, p = 0.001) after indomethacin, but not after ibuprofen [Figure 2], with a significant drug-by-time interaction (p = 0.029). Regarding urine output, ANOVA revealed no significant differences between drugs, although post-hoc tests showed a significant decrease in urine output only in the indomethacin group [Figure 2]. For the 131 neonates who received 2 or more total courses of treatment, there were significant decreases in urine output and increases in creatinine from baseline values, which were not significantly different between drugs [Figure 2]. Post hoc analyses revealed significant decreases in urine output from baseline observed during the last course of ibuprofen treatment (both by 0.9 mL/kg/hr, p < 0.05), in the subgroups receiving 2 or 3 courses [Figure 2]. Creatinine and urine output post-treatment returned to baseline values in both groups, regardless of the number of courses. Fluid intake was similar in both groups (data not shown).
Figure 2

Mean urine output and creatinine values by drug and number of courses. Comparison of mean urine output and creatinine values by treatment drug for subgroups and defined by the total number of courses received. Left panel: patients who received only one course of either ibuprofen or indomethacin. Middle panel: patients who received total of two courses. Right panel: patients who received 3 total courses of medical treatment. Indomethacin group (solid line) and Ibuprofen group (dashed line). PRE - pre-treatment baseline; 1st - end of first course of treatment, POST - 3-5 days after the last course of treatment. * denotes statistically significant (p < 0.05) change from baseline within a treatment group. § denotes statistically significant (p < 0.05) difference in change from baseline between treatment groups.

There was no difference in secondary outcomes between the two drugs, except for ROP and NEC-like illness. There was a significantly higher rate of ROP in the indomethacin group [Table 2]. However, there was no difference in the rate of severe ROP between the groups. There was a significantly higher rate of NEC-like illness in the indomethacin group (8% vs. 3% for ibuprofen, p = 0.03); conversely, there was a trend towards more frequent diagnosis of NEC in the ibuprofen group (8% vs. 4% for indomethacin, p = 0.08) [Table 2], but no difference in the rate of spontaneous intestinal perforations between the two treatment groups [Table 2].


The purpose of this study was to examine whether ibuprofen and indomethacin treatment of PDA have comparable effects on renal function as typically used in a NICU, where it is common for ELBW neonates to receive more than one course of cyclooxygenase inhibitor therapy in order to close the PDA. In addition to the renal effects, our observations on less common potential adverse effects of cyclooxygenase inhibitors add substantially to the available information on safety of these therapies, as this is the largest comparison study conducted in the US examining efficacy and side effects.

Van Overmeire et al. studied the efficacy of indomethacin and ibuprofen given to larger premature infants (≤32 weeks) at the age of 2-4 days. They reported that the closure rate was similar (66% and 70%, respectively) after the first course and that there was no significant difference in side effects, although ibuprofen was associated with significantly less impairment of renal function [5]. The study showed that infants of lower gestational age (<28 weeks) had a lower pharmacological closure rate and underwent surgical ligation more frequently. This and several other studies [11, 13, 21, 22, 23] found that there was similar efficacy in PDA closure when using indomethacin or ibuprofen. Most of these reports found that ibuprofen had fewer side effects than indomethacin. However, these studies enrolled small numbers of neonates, that were more mature (mean gestational age >28 weeks) than those in our study. Van Overmeire described 40 preterm infants most of whom required a single course of medical treatment; only 7 required a repeat course [23]. Su et al. compared efficacy and side effects of ibuprofen and indomethacin in neonates (≤ 28 weeks) with echographically present PDA. They found both efficacy and side effect profile to be the same in both groups, except for a greater tendency toward oliguria after one course of indomethacin compared to ibuprofen [16]. Because surgical ligation was performed if the PDA was still present after one course, that study does not elucidate effects on renal function with further medical treatment.

The findings of our study confirm that indomethacin has a more prominent initial effect on measures of renal function than ibuprofen. However, ibuprofen had a detrimental effect on renal function in the second and third courses equal to that of indomethacin. Both drugs had a similar overall detrimental effect on renal function, with repeated courses.

Other recent studies support the notion that ibuprofen therapy is not devoid of renal effects in neonates [24, 25, 26]. Gournay et al. noted an increase in creatinine in the prophylactic ibuprofen group and in those who received a second course of ibuprofen, which resolved in the second week of life. They also noted a decrease in urine output with ibuprofen as compared with placebo that returned to baseline after the first course. Ticker and Yildirim described temporary oliguria and/or renal dysfunction after treatment with one course of ibuprofen that is similar to that seen with indomethacin. Vieux et al. found a significant decrease in glomerular filtration and tubular function impairment in the ibuprofen group that was not seen in the patients who did not receive ibuprofen [25]. Richards et al. reported that the effectiveness of ibuprofen in closing a PDA decreased with a second course, and that creatinine was significantly higher in neonates receiving a second course as compared to controls [27].

Our study also adds information pertaining to the safety of cyclooxygenase inhibitor treatment. There was no difference in morbidities potentially associated with cyclooxygenase inhibitor therapy between patients receiving ibuprofen or indomethacin, except for the incidence of ROP and NEC-like disease. These findings may be incidental to secondary analyses, or they may hint at clinically significant relationships. The higher rate of ROP in the indomethacin group was related primarily to higher incidence of stages 1 and 2 diseases, not of severe ROP. This has not been seen in previous studies [23, 28, 29]. It is possible that the difference in ROP rates is related to the more stringent oxygen saturation targets implemented in 2006 [30].

In the ibuprofen group there was a trend towards a higher frequency of NEC, but not of spontaneous intestinal perforations [Table 2]; NEC-like disease was significantly less frequent. There was no increase in the incidence of NEC seen in other studies of ibuprofen [5] and this finding is unexpected since ibuprofen does not significantly reduce mesenteric blood-flow velocity [13]. Diagnostic drift is unlikely since neither neonatology nor radiology staff physicians changed during the study period; furthermore, diagnostic criteria in the database remained constant. However, over the last decade there has been an increase in the incidence of NEC in a nationally representative sample of NICUs, and our observation may reflect this background trend [31].

Since this study compares two historical cohorts, it is possible that unmeasured confounders may have changed over time, and affected the primary or secondary study outcomes. However, in our NICU, indomethacin and ibuprofen were used for treatment of PDA during two immediately contiguous eras. Because the switch in management occurred through mutual agreement of all neonatologists, indomethacin was exclusively used before October 2006 and ibuprofen thereafter. In our analysis we excluded the few patients who received both indomethacin and ibuprofen. The study comprises only a 4 year time span, so the effects of therapeutic drift should be minimal; furthermore, there were no other planned or perceived changes in clinical management related to PDA.

The larger number of patients evaluated in this study increased our ability to detect important differences in adverse events between the two drugs. Most of the previous studies, both retrospective and prospective, had lower numbers of patients enrolled [5, 11, 14, 16, 23, 29]. The retrospective nature of the study facilitated observation of the effects of both indomethacin and ibuprofen during unrestricted clinical usage. In particular, we demonstrated the consequences of repeated courses of cyclooxygenase inhibitor treatment in a large cohort of ELBW neonates.

This study confirms the findings or prior trials, revealing comparable effectiveness of indomethacin and ibuprofen in closing a PDA [11, 13, 21, 22, 23]. It also adds substantial weight to the notion that the likelihood of successful medical closure of the PDA diminishes with each subsequent course [27].

A limitation of our study is that it was retrospective. This allowed for some variability in treatment approaches by attending neonatologists; however, all clinicians used the same dosage regimen of PDA therapy and had similar approaches to PDA diagnosis. There was a wide range in the gestational age as well as acuity level of the neonates, which allows the results of this study to be more broadly generalizable. The larger proportion of males in the ibuprofen era is likely a chance finding, since review of our data on more than 1900 VLBW newborns over 14 years did not reveal a gender predilection of significant (treatable) PDAs or of PDA ligations. Furthermore, the gender difference between our study groups is unlikely to influence the results, since we found no gender-related differences in indices of renal function at baseline or in changes in urine output or creatinine during treatment courses.


In summary, our data indicated that both indomethacin and ibuprofen appear to have a similar overall effect on renal function, particularly with repeated courses of therapy. This effect may be clinically apparent with decreased urine output and potential fluid overload, and it is more prominent during the first course of indomethacin. Whereas a decrease in urine output of nearly 10 mL/kg/day may be anticipated during the first course of indomethacin therapy for PDA, both indomethacin and ibuprofen will produce a decrease in urine output of about 20 mL/kg/day during subsequent courses. These changes in renal function should be considered and reflected in fluid and electrolyte management by prospectively decreasing fluid intake by approximately 20 mL/kg/day, especially if treatment is required beyond one course.



I would like to acknowledge Dr. Angel Rios, Dr. Michael Horgan, and Dr. Rubia Khalak for the time they gave being on A.K.'s Scholarship Oversight Committee and overseeing the progress of this study.

Supplementary material

12908_2010_104_MOESM1_ESM.pdf (14 kb)
Authors’ original file for figure 1
12908_2010_104_MOESM2_ESM.pdf (177 kb)
Authors’ original file for figure 2


  1. 1.
    Evans N, Kluckow M: Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996, 75 (3): F183-F186. 10.1136/fn.75.3.F183.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Martin CG, Snider AR, Katz SM, Peabody JL, Brady JP: Abnormal cerebral blood flow patterns in preterm infants with a large patent ductus arteriosus. J Pediatr. 1982, 101 (4): 587-93. 10.1016/S0022-3476(82)80715-4.CrossRefPubMedGoogle Scholar
  3. 3.
    Wong SN, Lo RN, Hui PW: Abnormal renal and splanchnic arterial Doppler pattern in premature babies with symptomatic patent ductus arteriosus. J Ultrasound Med. 1990, 9 (3): 125-30.PubMedGoogle Scholar
  4. 4.
    Cotton RB, Stahlman MT, Kovar I, Catterton WZ: Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr. 1978, 92 (3): 467-73. 10.1016/S0022-3476(78)80451-X.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000, 343 (10): 674-81. 10.1056/NEJM200009073431001.CrossRefPubMedGoogle Scholar
  6. 6.
    Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE: Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976, 295 (10): 526-9. 10.1056/NEJM197609022951003.CrossRefPubMedGoogle Scholar
  7. 7.
    Heymann MA, Rudolph AM, Silverman NH: Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976, 295 (10): 530-3. 10.1056/NEJM197609022951004.CrossRefPubMedGoogle Scholar
  8. 8.
    Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS: Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981, 68 (1): 99-102.PubMedGoogle Scholar
  9. 9.
    van Bel F, Guit GL, Schipper J, van de Bor M, Baan J: Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr. 1991, 118 (4 (Pt 1)): 621-6.CrossRefPubMedGoogle Scholar
  10. 10.
    Edwards AD, Wyatt JS, Richardson C, Potter A, Cope M, Delpy DT, Reynolds EO: Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990, 335 (8704): 1491-5. 10.1016/0140-6736(90)93030-S.CrossRefPubMedGoogle Scholar
  11. 11.
    Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV: Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996, 275 (7): 539-44. 10.1001/jama.275.7.539.CrossRefPubMedGoogle Scholar
  12. 12.
    Romagnoli C, De Carolis MP, Papacci P, Polimeni V, Luciano R, Piersigilli F, Delogu AB, Tortorolo G: Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther. 2000, 67 (6): 676-83. 10.1067/mcp.2000.107048.CrossRefPubMedGoogle Scholar
  13. 13.
    Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF: Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr. 1999, 135 (6): 733-8. 10.1016/S0022-3476(99)70093-4.CrossRefPubMedGoogle Scholar
  14. 14.
    Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia OS: Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. 2002, 161 (4): 202-7. 10.1007/s00431-002-0915-y.CrossRefPubMedGoogle Scholar
  15. 15.
    Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C: Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr. 1997, 131 (4): 549-54. 10.1016/S0022-3476(97)70060-X.CrossRefPubMedGoogle Scholar
  16. 16.
    Su BH, Lin HC, Chiu HY, Hsieh HY, Chen HH, Tsai YC: Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008, 93 (2): F94-F99.CrossRefPubMedGoogle Scholar
  17. 17.
    Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T: Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978, 187 (1): 1-7. 10.1097/00000658-197801000-00001.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Vermont Oxford Network Database: Manual of Operations. 2007, Burlington, VT: Vermont Oxford Network, Release 12.0Google Scholar
  19. 19.
    International Committee for the Classification of Retinopathy of Prematurity: The International Classification of Retinopathy of Prematurity Revisited. 2005, 991-9. 123Google Scholar
  20. 20.
    Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978, 92 (4): 529-34. 10.1016/S0022-3476(78)80282-0.CrossRefPubMedGoogle Scholar
  21. 21.
    Clyman RI: Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000, 343 (10): 728-30. 10.1056/NEJM200009073431009.CrossRefPubMedGoogle Scholar
  22. 22.
    Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD: Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. 2000, 47 (1): 36-42. 10.1203/00006450-200001000-00009.CrossRefPubMedGoogle Scholar
  23. 23.
    Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ: Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed. 1997, 76 (3): F179-F184. 10.1136/fn.76.3.F179.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tiker F, Yildirim SV: Acute renal impairment after oral ibuprofen for medical closure of patent ductus arteriosus. Indian Pediatr. 2007, 44 (1): 54-5.PubMedGoogle Scholar
  25. 25.
    Vieux R, Desandes R, Boubred F, Semama D, Guillemin F, Buchweiller MC, Fresson J, Hascoet JM: Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol. 2010, 25 (2): 267-74. 10.1007/s00467-009-1349-9.CrossRefPubMedGoogle Scholar
  26. 26.
    Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, Chamboux C, Blanc T, Fichtner C, Savagner C, Gouyon JB, Flurin V, Thiriez G: Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2004, 364 (9449): 1939-44. 10.1016/S0140-6736(04)17476-X.CrossRefPubMedGoogle Scholar
  27. 27.
    Richards J, Johnson A, Fox G, Campbell M: A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics. 2009, 124 (2): e287-e293. 10.1542/peds.2008-2232.CrossRefPubMedGoogle Scholar
  28. 28.
    Aranda JV, Clyman R, Cox B, Van Overmeire B, Wozniak P, Sosenko I, Carlo WA, Ward RM, Shalwitz R, Baggs G, Seth A, Darko L: A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol. 2009, 26 (3): 235-45. 10.1055/s-0028-1103515.CrossRefPubMedGoogle Scholar
  29. 29.
    Cotton RB, Stahlman MT, Bender HW, Graham TP, Catterton WZ, Kovar I: Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants. J Pediatr. 1978, 93 (4): 647-51. 10.1016/S0022-3476(78)80910-X.CrossRefPubMedGoogle Scholar
  30. 30.
    SUPPORT Study Group of the Eunice Kennedy Shriver NICHDNeonatal Research Network: Target Ranges of Oxygen Saturation in Extremely Preterm Infants. N Engl J Med. 2010, 362 (21): 1959-69.CrossRefGoogle Scholar
  31. 31.
    Vermont Oxford Network: Vermont Oxford Network Database: 2009 Annual NICU Quality Management Report. 2010, Burlington, VT, Vermont Oxford NetworkGoogle Scholar

Pre-publication history

  1. The pre-publication history for this paper can be accessed here:

Copyright information

© Kushnir and Pinheiro; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Authors and Affiliations

  1. 1.Division of NeonatologyDepartment of PediatricsAlbanyUSA
  2. 2.Division of NeonatologyDepartment of PediatricsCamdenUSA

Personalised recommendations